Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors
Standard
Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors. / Weidemann, Sören; Gagelmann, Pauline; Gorbokon, Natalia; Lennartz, Maximilian; Menz, Anne; Luebke, Andreas M; Kluth, Martina; Hube-Magg, Claudia; Blessin, Niclas C; Fraune, Christoph; Möller, Katharina; Bernreuther, Christian; Lebok, Patrick; Clauditz, Till S; Jacobsen, Frank; Izbicki, Jakob R; Jansen, Kristina; Sauter, Guido; Uhlig, Ria; Wilczak, Waldemar; Steurer, Stefan; Minner, Sarah; Burandt, Eike; Krech, Rainer H; Dum, David; Krech, Till; Marx, Andreas H; Simon, Ronald.
in: BIOMEDICINES, Jahrgang 9, Nr. 4, 397, 07.04.2021.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors
AU - Weidemann, Sören
AU - Gagelmann, Pauline
AU - Gorbokon, Natalia
AU - Lennartz, Maximilian
AU - Menz, Anne
AU - Luebke, Andreas M
AU - Kluth, Martina
AU - Hube-Magg, Claudia
AU - Blessin, Niclas C
AU - Fraune, Christoph
AU - Möller, Katharina
AU - Bernreuther, Christian
AU - Lebok, Patrick
AU - Clauditz, Till S
AU - Jacobsen, Frank
AU - Izbicki, Jakob R
AU - Jansen, Kristina
AU - Sauter, Guido
AU - Uhlig, Ria
AU - Wilczak, Waldemar
AU - Steurer, Stefan
AU - Minner, Sarah
AU - Burandt, Eike
AU - Krech, Rainer H
AU - Dum, David
AU - Krech, Till
AU - Marx, Andreas H
AU - Simon, Ronald
PY - 2021/4/7
Y1 - 2021/4/7
N2 - Mesothelin (MSLN) represents an attractive molecule for targeted cancer therapies. To identify tumors that might benefit from such therapies, tissue microarrays including 15,050 tumors from 122 different tumor types and 76 healthy organs were analyzed for MSLN expression by immunohistochemistry. Sixty-six (54%) tumor types showed at least occasional weak staining, including 50 (41%) tumor types with at least one strongly positive sample. Highest prevalence of MSLN positivity had ovarian carcinomas (serous 97%, clear cell 83%, endometrioid 77%, mucinous 71%, carcinosarcoma 65%), pancreatic adenocarcinoma (ductal 75%, ampullary 81%), endometrial carcinomas (clear cell 71%, serous 57%, carcinosarcoma 50%, endometrioid 45%), malignant mesothelioma (69%), and adenocarcinoma of the lung (55%). MSLN was rare in cancers of the breast (7% of 1138), kidney (7% of 807), thyroid gland (1% of 638), soft tissues (0.3% of 931), and prostate (0 of 481). High expression was linked to advanced pathological tumor (pT) stage (p < 0.0001) and metastasis (p < 0.0001) in 1619 colorectal adenocarcinomas, but unrelated to parameters of malignancy in 1072 breast-, 386 ovarian-, 174 lung-, 757 kidney-, 171 endometrial-, 373 gastric-, and 925 bladder carcinomas. In summary, numerous important cancer types with high-level MSLN expression might benefit from future anti-MSLN therapies, but MSLN's prognostic relevance appears to be limited.
AB - Mesothelin (MSLN) represents an attractive molecule for targeted cancer therapies. To identify tumors that might benefit from such therapies, tissue microarrays including 15,050 tumors from 122 different tumor types and 76 healthy organs were analyzed for MSLN expression by immunohistochemistry. Sixty-six (54%) tumor types showed at least occasional weak staining, including 50 (41%) tumor types with at least one strongly positive sample. Highest prevalence of MSLN positivity had ovarian carcinomas (serous 97%, clear cell 83%, endometrioid 77%, mucinous 71%, carcinosarcoma 65%), pancreatic adenocarcinoma (ductal 75%, ampullary 81%), endometrial carcinomas (clear cell 71%, serous 57%, carcinosarcoma 50%, endometrioid 45%), malignant mesothelioma (69%), and adenocarcinoma of the lung (55%). MSLN was rare in cancers of the breast (7% of 1138), kidney (7% of 807), thyroid gland (1% of 638), soft tissues (0.3% of 931), and prostate (0 of 481). High expression was linked to advanced pathological tumor (pT) stage (p < 0.0001) and metastasis (p < 0.0001) in 1619 colorectal adenocarcinomas, but unrelated to parameters of malignancy in 1072 breast-, 386 ovarian-, 174 lung-, 757 kidney-, 171 endometrial-, 373 gastric-, and 925 bladder carcinomas. In summary, numerous important cancer types with high-level MSLN expression might benefit from future anti-MSLN therapies, but MSLN's prognostic relevance appears to be limited.
U2 - 10.3390/biomedicines9040397
DO - 10.3390/biomedicines9040397
M3 - SCORING: Journal article
C2 - 33917081
VL - 9
JO - BIOMEDICINES
JF - BIOMEDICINES
SN - 2227-9059
IS - 4
M1 - 397
ER -